• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    5/8/25 7:15:40 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email
    0001557746false00015577462025-05-082025-05-08

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): May 8, 2025

    ​

    ​

    Aclaris Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

    ​

    001-37581

    ​

    46-0571712

    (State or other jurisdiction of incorporation)

    ​

    (Commission File Number)

    ​

    (IRS Employer
    Identification No.)

    ​

    701 Lee Road, Suite 103

    Wayne, PA 19087

    (Address of principal executive offices, including zip code)

    ​

    (484) 324-7933

    (Registrant’s telephone number, including area code)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act: 

     

     

     

     

     

    Title of Each Class:

     

    Trading Symbol(s)

     

    Name of Each Exchange on which Registered

    Common Stock, $0.00001 par value

     

    ACRS

     

    The Nasdaq Stock Market, LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition.

    ​

    On May 8, 2025, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report.

    ​

    In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

    ​

    Item 7.01 Regulation FD Disclosure.

    On May 8, 2025, the Registrant updated its corporate overview presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The updated corporate overview presentation is also available on the Registrant’s website.

    In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.2 hereto shall not be deemed “filed” for purposes of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

    ​

    Item 9.01 Financial Statements and Exhibits.

    ​

    (d) Exhibits

    ​

    ​

    ​

    Exhibit

    ​

     

    Number

    ​

    Exhibit Description

    99.1

    ​

    Press Release, dated May 8, 2025.

    99.2

    ​

    Company Presentation.

    104

    ​

    The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on May 8, 2025, formatted in Inline XBRL.

    ​

    ​

    ​

    2

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

      

    ​

    ​

    ​

    ​

    ACLARIS THERAPEUTICS, INC.

    ​

    ​

    ​

    Date: May 8, 2025

    By:  

    /s/ Kevin Balthaser

    ​

    Kevin Balthaser
    Chief Financial Officer

    ​

    ​

    ​

    3

    Get the next $ACRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACRS

    DatePrice TargetRatingAnalyst
    3/18/2025Overweight
    Cantor Fitzgerald
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    11/18/2024$3.00 → $13.00Neutral → Overweight
    Piper Sandler
    1/22/2024Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ACRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series

      WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright "HCW@Home" series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days. About Ac

      5/9/25 7:00:19 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

      5/8/25 6:50:51 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

      WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

      4/29/25 7:00:32 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Hall Jesse Wayne

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:32:56 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hall Jesse Wayne

      3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:29:44 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 2,975 shares, increasing direct ownership by 0.44% to 1,479,824 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:20:04 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Financials

    Live finance-specific insights

    See more

    $ACRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ACRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ACRS
    SEC Filings

    See more

    $ACRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

      5/8/25 6:50:51 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

      - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf

      2/27/25 6:59:55 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

      - Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) --  Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl

      11/18/24 8:10:04 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

      Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

      3/18/25 8:23:58 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $20.00

      12/23/24 7:21:33 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight

      11/20/24 3:46:36 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      11/20/24 4:20:04 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      8/5/24 3:57:34 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      7/31/24 4:10:09 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Aclaris Therapeutics Inc.

      10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      5/8/25 4:30:29 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      5/8/25 7:15:40 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Aclaris Therapeutics Inc.

      SCHEDULE 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      5/5/25 4:00:33 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/25/24 11:02:19 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/22/24 4:00:23 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/21/24 4:51:50 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

      WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

      4/29/25 7:00:32 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

      CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.

      4/23/24 8:00:00 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Key Leadership Transitions

      - Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder

      11/22/22 4:01:00 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care